Investment Summary |
|
|---|---|
| Date | 2014-10-31 |
| Target | New Zealand New Milk |
| Sector | Food |
| Investor(s) | Aspen Pharmacare |
| Deal Type | Stake Purchase |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1850 |
| Sector | Life Science |
| Employees | 8,867 |
| Revenue | 44.7B ZAR (2024) |
Aspen Pharmacare is a provider of specialty, branded, and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries. In line with the Group’s commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics, high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the highest focus based on materiality and future potential. Aspen Pharmacare was founded in 1850 and is based in Durban, South Africa.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Food M&A | 1 of 1 |
| Type: Stake Purchase M&A Deals | 1 of 1 |
| Country: New Zealand M&A | 1 of 1 |
| Year: 2014 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-09-30 |
GlaxoSmithKline - Arixtra & Fraxiparine/Fraxodi Brands
United Kingdom GlaxoSmithKline - Arixtra & Fraxiparine/Fraxodi Brands is a specialised sterile production site which manufactures the Brands at Notre Dame de Bondeville, France . Arixtra and Fraxiparine/Fraxodi are made at a sterile site and the ability to manufacture steriles is globally recognised as a specialist activity resulting in limited possible competition. This is a factor further underlined by the increased complexity of the manufacturing process of Fraxiparine/Fraxodi due to the biological nature of the active pharmaceutical ingredients (“API”) used in their production. |
Buy | £700M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-08 |
Aspen Pharmacare Holdings - Thrombosis Business
United Kingdom Aspen Pharmacare's Thrombosis Business is a global offering comprised largely of a broad range of specialist injectable anticoagulants. Aspen's portfolio also includes Orgaran which is a heparin derivative (heparinoid) indicated for the treatment of HIT. HIT is an adverse reaction occurring in a limited number of patients undergoing heparin related therapy. It offers healthcare providers the advantage of a single supplier that addresses broad clinical needs and thus ensures the optimal care of patients at risk of thrombosis. |
Sell | €642M |
